Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.42 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68869 | 0.91 | MAPK1 (0.63) | KDM4EMAPK1L3MBTL1SIRT6LCK | |
| SCHEMBL990711 | 0.83 | MAPK1 (0.55) | KDM4EMAPK1L3MBTL1SIRT6LCK | |
| SCHEMBL428719 | 0.81 | MAPK1 (0.53) | KDM4EMAPK1L3MBTL1SIRT6LCK | |
| SCHEMBL1858691 | 0.81 | POLB (0.59) | MAPK1L3MBTL1ALDH1A1LMNACYP1A2 | |
| SCHEMBL70035 | 0.81 | KDM4E (0.59) | KDM4EMAPK1L3MBTL1SIRT6HCAR2 | |
| SCHEMBL544241 | 0.79 | MAPK1 (0.52) | KDM4EMAPK1L3MBTL1SIRT6LCK | |
| SCHEMBL2134366 | 0.79 | MAPK1 (0.52) | KDM4EMAPK1L3MBTL1SIRT6LCK | |
| SCHEMBL22119742 | 0.79 | MAPK1 (0.52) | KDM4EMAPK1L3MBTL1SIRT6LCK | |
| SCHEMBL64740 | 0.79 | SIRT6 (0.57) | KDM4EMAPK1L3MBTL1SIRT6LCK | |
| SCHEMBL13067536 | 0.79 | MAPK1 (0.52) | KDM4EMAPK1L3MBTL1SIRT6LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076594-A | Sulfonylpiperazinyl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3390361-B1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORP (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210363137-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-11-25 | — | — | US | disclosed |
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| WO-2021007313-A1 | WNT ACTIVATORS AND METHODS OF USE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-01-14 | — | — | WO | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107108597-B | Dopamine D3 receptor antagonist compounds | 英立维尔英国有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2020069125-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | disclosed |
| WO-2016067043-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1105775-B1 | POLYHALIDE PARTICLES AND LIGHT VALVES COMPRISING SAME | RESEARCH FRONTIERS INC (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1105775-A4 | POLYHALIDE PARTICLES AND LIGHT VALVES COMPRISING SAME | RESEARCH FRONTIERS INC (US) | 2005-04-13 | — | — | EP | disclosed |
| US-6517746-B1 | Polarizing material is a complex of (a) elemental iodine; (b) a hydrohalide acid or an ammonium, alkali metal or alkaline earth halide; (c) a pyrazine-2,5-dicarboxylic acid; and (d) a monoamide or monoester of a pyrazine-2,5-dicarboxylic acid | RESEARCH FRONTIERS INCORPORATED | 2003-02-11 | — | — | US | disclosed |
| EP-1105775-A1 | POLYHALIDE PARTICLES AND LIGHT VALVES COMPRISING SAME | RESEARCH FRONTIERS INCORPORATED (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000003178-A1 | POLYHALIDE PARTICLES AND LIGHT VALVES COMPRISING SAME | RESEARCH FRONTIERS INCORPORATED (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | KDM4E 3324/4885MAPK1 2227/4885L3MBTL1 3137/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | KDM4E 2877/4885MAPK1 1646/4885L3MBTL1 2593/4885 |
| US-20210363137-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | KDM4E 3674/4885MAPK1 3884/4885L3MBTL1 4158/4885 |
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | HAVCR2, CUL4A, PSMC3 | KDM4E 693/4885MAPK1 4642/4885L3MBTL1 2792/4885 |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | KDM4E 3674/4885MAPK1 3884/4885L3MBTL1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.